Dyspnea intravenous

Alkyl olefinsulfonates (AOS) are essentially nontoxic with reported LD50 values in mice of 3000 mg/kg (oral), 1660 mg/kg (subcutaneous), 170 mg/kg (intraperitoneal), and 90 mg/kg (intravenous). The toxic signs seen at the higher doses included reduced voluntary activity, diarrhea, anemia, dyspnea, and respiratory collapse. Clonic convulsion followed by respiratory collapse was seen in mice given the material intravenously [147,148]. 

In patients receiving infliximab, monitor for infusion-related reactions such as hypotension, dyspnea, fever, chills, or chest pain when administering intravenous doses. 

Elemental Be and its compounds are very poisonous by inhalation or intravenous route. Chronic inhalation of beryUium dusts or fumes can cause a serious lung disease, beryUiosis, after a latent period ranging from several months to many years. Inhalation of airborne dusts can also cause an acute disease manifested as dyspnea, pneumonitis and tracheobronchitis with a short latency period of a few days. Skin contact with soluble salts of the metal can cause dermatitis. Beryllium also is a carcinogen. There is sufficient evidence of its inducing cancer in animals and humans. 

Hypoprothrombinemia may occur in malabsorption syndromes and also the use of broad-spectrum antibiotics may produce a hypoprothrombinemia that responds readily to small doses of vitamin K. In premature infants and in infants with hemorrhagic disease of the newborn the use of vitamin K may be indicated. However, the main indication for the use of vitamin K is to antagonize the anticoagulant activity of coumarins. Oral absorption of phytonadione and the menaquinones is by the lymph while menadione and its water-soluble derivatives are absorbed directly. The absorption of phytonadione is energy-dependent and saturable. Intravenous administration of phytonadione has produced flushing, dyspnea, chest pains, and cardiovascular collapse. 

The relief produced by intravenous morphine in dyspnea from pulmonary edema associated with left ventricular heart failure is remarkable. Proposed mechanisms include reduced anxiety (perception of shortness of breath), and reduced cardiac preload (reduced venous tone) and afterload (decreased peripheral resistance). However, if respiratory depression is a problem, furosemide may be preferred for the treatment of pulmonary edema. On the other hand, morphine can be particularly useful when treating painful myocardial ischemia with pulmonary edema. 

Vitamins Ki and K2 require bile salts for absorption from the intestinal tract. Vitamin Kl is available clinically in oral and parenteral forms. Onset of effect is delayed for 6 hours but the effect is complete by 24 hours when treating depression of prothrombin activity by excess warfarin or vitamin deficiency. Intravenous administration of vitamin Ki should be slow, because rapid infusion can produce dyspnea, chest and back pain, and even death. Vitamin repletion is best achieved with intravenous or oral administration, because its bioavailability after subcutaneous administration is erratic. Vitamin Ki is... 

Pentamidine is a highly toxic drug, with adverse effects noted in about 50% of patients receiving 4 mg/kg/d. Rapid intravenous administration can lead to severe hypotension, tachycardia, dizziness, and dyspnea, so the drug should be administered slowly (over 2 hours), and patients should be recumbent and monitored closely during treatment. With intramuscular administration, pain at the injection site is common, and sterile abscesses may develop. 

Infliximab intravenous infusions result in acute adverse infusion reactions in up to 10% of patients, but discontinuation of the infusion for severe reactions is required in less than 2%. Infusion reactions are more common with the second or subsequent infusions than with the first. Early mild reactions include fever, headache, dizziness, urticaria, or mild cardiopulmonary symptoms that include chest pain, dyspnea, or hemodynamic instability. Reactions to subsequent infusions may be reduced with prophylactic administration of acetaminophen, diphenhydramine, or corticosteroids. Severe acute reactions include significant hypotension, shortness of breath, muscle spasms, and chest discomfort such reactions may require treatment with oxygen, epinephrine, and corticosteroids. 

Angioedema has been reported in an obese woman after she had taken pioglitazone 30 mg/day for 7 days (130). She developed a sore throat followed by dyspnea and swelling of the lips and tongue. There was no rash. After intravenous glucocorticoids her symptoms rapidly abated. 

When salmon calcitonin 100 IU was given intravenously to 18 patients with atopic asthma in a randomized, double-blind, crossover study, to assess any potential antiinflammatory effect, it significantly reduced FEV1 and FVC, but the effect lasted less than 1 hour (11). Three subjects had dyspnea that did not require specific treatment. 

Intravenous bolus doses of 1 mg/kg produce transient facial flushing and, rarely, dyspnea. Adrenocorticotropin (Corticotropin, ACTH, ACTH, 24)... 

Na2W04 -2H20, injected subcutaneously in adult rats, LD5Q is 140—160 mg W/kg. Death results from generalized cellular asphyxiation. Guinea pigs treated orally or intravenously with Na WC ZH O suffered anorexia, colic, incoordination of movement, trembling, and dyspnea. 

Based on the experience of Iranian physicians who treated sarin toxicity during the Iran-Iraq war (Newmark, 2004), PAM was not available on the front lines and atropine alone was used for treatment. The doses of atropine used were considerably higher than those used in the Tokyo subway sarin attack, or that are generally recommended in the USA (Medical Letter, 2002). The Iranian protocol called for initial administration of 4 mg intravenously. If no atropine effects (improvement in dyspnea or decrease in airway secretions) were seen after 1 to 2 min, 5 mg was then administered intravenously over 5 min while heart rate was monitored. A rise in heart rate of 20 to 30 beats per min was regarded as an atropine effect. In severe cases, 20 mg to 200 mg was given. Regardless of dose, the key to saving lives, in their opinion, was how soon the atropine was administered. 

SAFETY PROFILE Poison by subcutaneous and intravenous routes. Moderately toxic by intraperitoneal route. Human systemic effects by ingestion dyspnea. An experimental teratogen by many routes. Other experimental reproductive effects. When heated to decomposition it emits ver toxic fumes of NOx and SOx. A carbonic anhydrase inhibitor and diuretic used to treat glaucoma. 

DOT CLASSIFICATION 6.1 Label KEEP AWAY FROM FOOD SAFETY PROFILE Human poison by intravenous route, producing liver and kidney changes, somnolence, dyspnea, and pupillary dilation. Poison by ingestion, subcutaneous, intravenous, intramuscular, and intraperitoneal routes. Large doses cause severe liver damage. Human mutation data reported. Used medicinally, the therapeutic dose is close to the toxic dose. Upon decomposition it emits toxic fumes of K2O and Sb. 

SAFETY PROFILE Poison by ingestion, intravenous, intracerebral, intraspinal, subcutaneous, and possibly other routes. Human (child) systemic effects by parenteral route changes in cochlear (inner ear) structure or function, convulsions, and dyspnea. Questionable carcinogen with experimental tumorigenic data. Mutation data reported. When heated to decomposition it emits very toxic fiimes of NOx and SO. See other penicillin entries. 

SAFETY PROFILE Confirmed carcinogen with experimental carcinogenic, neoplastigenic, and tumorigenic data. A deadly poison by intravenous route. Human systemic effects by inhalation lung fibrosis, dyspnea, and weight loss. Human mutation data reported. See also BERYLLIUM COMPOUNDS. A moderate fire hazard in the form of dust or powder, or when exposed to flame or by spontaneous chemical reaction. Slight explosion hazard in the form of powder or dust. Incompatible with halocarbons. Reacts incandescently with fluorine or chlorine. Mixtures of the powder with CCU or trichloroethylene will flash or spark on impact. When heated to decomposition in air it emits very toxic fumes of BeO. Reacts with Li and P. 

CONSENSUS REPORTS lARC Cancer Review Group 2B IMEMDT 7,134,87 Human Inadequate Evidence IMEMDT 26,97,81. EPA Genetic Toxicology Program. SAFETY PROFILE A human poison by intravenous route moderately toxic to humans by intramuscular route. Poison experimentally by intravenous and intraperitoneal routes. Human systemic effects by ingestion and intramuscular routes dyspnea and fibrosing alveolitis (lung). Experimental reproductive effects. 

OSHA PEL TWA 0.05 ppm ACGIH TLV TWA 0.05 ppm Not Classifiable as a Human Carcinogen DOT CLASSIFICATION 6.1 Label Poison SAFETY PROFILE A human poison by inhalation. An experimental poison by ingestion, inhalation, intraperitoneal, and intravenous routes. Human systemic effects by inhalation lachrymation, conjunctiva irritation, and unspecified eye effects, cough, and dyspnea. A severe eye and moderate skin irritant. Questionable carcinogen with experimental neoplastigenic data by skin contact. A riot control agent. When heated to decomposition it emits toxic fumes of Cr. See also KETONES. 

SAFETY PROFILE Poison by ingestion, intravenous, intraperitoneal, and subcutaneous routes. Human systemic effects blood pressure lowering, changes in heart rate, coma, convulsions, distorted perceptions, dyspnea, excitement, hallucinations, muscle contraction or spasticity, pulse rate, respiratory depression, toxic psychosis. An experimental teratogen. Other experimental reproductive effects. A local anesthetic. Mutation data reported. When heated to decomposition it emits toxic fumes of NOx. 

---